Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting
agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and
some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG
in detecting a certain type of inflammations according to our preliminary research. Thus this
prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for
diagnosis, therapy response assessment and follow-up of Pulmonary fibrosis than 18F-FDG
PET/CT.